You are here: Home » Companies » News
Business Standard

RPG Life launches drug to delay dialysis in kidney patients

Press Trust of India  |  Mumbai 

RPG Group's pharma arm today launched an indigenously developed drug, which it claimed, would delay the renal replacement therapy (dialysis) among chronic kidney failure patients.

'Ketoanalogue' (generic name of the brand Alfalog), has been developed, manufactured by RPG Life Sciences, the pharma and biotech arm of the multi-billion RPG Group.

When administered in the early stages of chronic kidney failure patients, Ketoanalogue would delay the stage of reaching the process of dialysis at least by two to three years, RPG Life Sciences Managing Director Ajit Singh Chouhan told reporters here.

This is the first indigenously researched, developed and manufactured Ketoanalogue, he said, adding so far India has been importing the medicine from Fresenius Kabi, the original inventor.

"The product is a complex mix of 10 active ingredients (amino acids). The technological breakthrough allows the product to remain stable and have better dissolution," he said, adding it has received Food and Drug Administration (FDA)'s approval.

"The product, being very sensitive to temperature and moisture, needs to have high stability since instability increases the impurity levels. Better dissolution of the drug ensures better bio-availability, optimising the therapeutic effects," he explained.

After cyclosporin, (immunosuppressant used in patients undergoing transplantation) this is one more technological innovation from RPG Life, Chouhan said.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, January 05 2011. 19:47 IST